Ainos (AIMD) Stock Price, News & Analysis

Company Overview

Ainos, Inc. (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format. AI‐401 is engineered to target airway inflammation in conditions such as cystic fibrosis and other chronic respiratory diseases. In preclinical studies, the formulation demonstrated favorable pulmonary deposition and sustained release, and it has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of cystic fibrosis.

In addition to AI‐401, Ainos is exploring the application of its dry powder inhalation technology for other anti‐inflammatory and anti‐infective agents, with the goal of expanding its pipeline into multiple respiratory indications. The company collaborates with contract development and manufacturing organizations (CDMOs) to advance product candidates through formulation optimization, toxicology assessments and early clinical trials.

Founded in the United States, Ainos is headquartered in Philadelphia and serves patients and healthcare providers primarily in North America and Europe. The company’s management team comprises executives with extensive experience in respiratory drug development, regulatory affairs and commercial strategy. Ainos aims to leverage its inhalation platform to bring novel pulmonary therapies to market and address unmet medical needs in chronic lung disease.

Key Stats

• Today's Range: $3.36 to $3.61
• 50-Day Range: $2.33 to $4.11
• 52-Week Range: $2.00 to $5.00
• Volume: 39,979 shs
• Average Volume: 903,380 shs
• Market Capitalization: $15.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Ainos Stock Analysis - MarketRank™

Ainos scored higher than 21% of companies evaluated by MarketBeat, and ranked 876th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Ainos.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Ainos is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ainos is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ainos has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.09% of the float of Ainos has been sold short.

Short Interest Ratio / Days to Cover

Ainos has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ainos has recently decreased by 17.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ainos does not currently pay a dividend.

Dividend Growth

Ainos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.09% of the float of Ainos has been sold short.

Short Interest Ratio / Days to Cover

Ainos has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Ainos has recently decreased by 17.41%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Ainos has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Ainos this week, compared to 0 articles on an average week.

MarketBeat Follows

Only 1 people have added Ainos to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ainos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $23,569.00 in company stock.

Percentage Held by Insiders

10.39% of the stock of Ainos is held by insiders. A high percentage of insider ownership can be a sign of company health.

AIMD Stock Analysis - Frequently Asked Questions

How have AIMD shares performed this year?

Ainos' stock was trading at $2.28 at the beginning of 2025. Since then, AIMD shares have increased by 49.1% and is now trading at $3.40.

How were Ainos' earnings last quarter?

Ainos, Inc. (NASDAQ:AIMD) released its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.99) earnings per share (EPS) for the quarter.

When did Ainos' stock split?

Ainos shares reverse split before market open on Thursday, December 14th 2023.The 1-5 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

When did Ainos IPO?

Ainos (AIMD) raised $3 million in an IPO on Tuesday, August 9th 2022. The company issued 800,000 shares at a price of $4.25 per share. Maxim Group served as the underwriter for the IPO and Brookline Capital Markets was co-manager.

How do I buy shares of Ainos?

Shares of AIMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ainos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ainos investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON), Jabil (JBL) and Adobe (ADBE).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AIMD
• Previous Symbol: NASDAQ:AIMD
• CIK: 1014763
• Web: www.ainos.com
• Phone: 858-869-2986
• Fax: 806-376-9301
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.99)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.86 million
• Net Margins: N/A
• Pretax Margin: -14,164.87%
• Return on Equity: -108.25%
• Return on Assets: -56.94%

Debt

• Debt-to-Equity Ratio: 0.96
• Current Ratio: 2.88
• Quick Ratio: 2.61

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 829.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.51 per share
• Price / Book: 0.65

Miscellaneous

• Outstanding Shares: 4,660,000
• Free Float: 4,174,000
• Market Cap: $16.59 million
• Optionable: Not Optionable
• Beta: 2.25